Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $309 | $271 | $239 | $200 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Cost of Goods Sold | $134 | $114 | $1 | $1 |
| Gross Profit | $175 | $157 | $1 | $1 |
| % Margin | 56.7% | 58.1% | 0.4% | 0.5% |
| R&D Expenses | $15 | $13 | $0 | $0 |
| G&A Expenses | $0 | $0 | -$46 | -$37 |
| SG&A Expenses | $58 | $54 | $1 | $1 |
| Sales & Mktg Exp. | $58 | $54 | $46 | $38 |
| Other Operating Expenses | $64 | $50 | $0 | $0 |
| Operating Expenses | $136 | $117 | $1 | $1 |
| Operating Income | $39 | $40 | $34 | $29 |
| % Margin | 12.6% | 14.8% | 14.2% | 14.5% |
| Other Income/Exp. Net | $3 | $1 | $0 | -$1 |
| Pre-Tax Income | $42 | $42 | $34 | $28 |
| Tax Expense | $11 | $10 | $8 | $7 |
| Net Income | $31 | $31 | $26 | $21 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS | 136.11 | 135.6 | 115.62 | 92.61 |
| % Growth | 0.4% | 17.3% | 24.8% | – |
| EPS Diluted | 135.44 | 135.21 | 115.29 | 92.34 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $13 | $9 | $8 | $8 |
| EBITDA | $56 | $50 | $42 | $36 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |